B

T3 (stage III) laryngeal cancers are considered “locally advanced.” Current guidelines recommend an organ-preservation approach with definitive radiotherapy given concurrently with cisplatin-based chemotherapy; this provides local control and survival equivalent to total laryngectomy while preserving the voice. [Jones 2016, PMID 27841116; Forastiere 2018, PMID 29172863]